Iveson, Professor Tim

Dr Tim IvesonBSc, MB BS, MD, FRCP

Specialty

Medical oncology

Sub-specialty

Gastrointestinal cancers (oesophagus, stomach, pancreas, biliary tract and colorectal)

Training and education

  • MB BS (undergraduate medical degree) - St Bartholomew's Hospital medical school, 1984
  • Postgraduate medical oncology training - Royal Marsden Hospital
  • MD - University of London, 1996
  • FRCP (fellow of the Royal College of Physicians) - 2000

Experience

Prof Iveson has worked for the Trust since November 1995. 

He has wide experience in the chemotherapy treatment of all gastrointestinal cancers. 

Key achievements

  • Professor of gastrointestinal oncology since 2019
  • Care group lead for cancer care since 2017
  • Lead cancer clinician at University Hospital Southampton since 2015
  • Chief medical editor for Macmillan since 2012
  • Member of Macmillan's clinical advisory board
  • Member of Bowel Cancer UK's medical advisory board

Research

Prof Iveson is active in clinical trials investigating the chemotherapy treatment of gastrointestinal cancers, and has widely published the results of these trials in peer-reviewed journals. He's also presented the results at national and international meetings.

Prof Iveson is the chief investigator of the SCOT study and a member of the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) steering committee. The SCOT and IDEA studies investigated the duration of adjuvant chemotherapy for bowel cancer and showed that for many patients, the duration of treatment can be reduced from six to three months.